CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2021—Mesa Laboratories has entered into a definitive agreement to acquire Agena Bioscience for a cash price of $300 million, subject to customary purchase price adjustments. The transaction is expected to be completed by Dec. 31 and is subject to customary conditions, including receipt of applicable regulatory approvals.
“We are proud of our track record in bringing the power of genomics to the clinical setting in hereditary diseases, pharmacogenomics, oncology, infectious disease, and sample integrity testing,” said Peter Dansky, chief executive officer of Agena, who will join Mesa to lead a new clinical genomics division. “Our robust technology platform along with deep customer partnership has been the foundation of our success. We built our company based on a strong team-oriented values system, and we see a great fit with the Mesa culture. We look forward to working with the Mesa team to expand the applications we deliver and innovate new technologies for clinical genomics.”